Category Ranking
98%
Total Visits
921
Avg Visit Duration
2 minutes
Citations
20
Article Abstract
In September 2023, CDC's Advisory Committee on Immunization Practices recommended updated 2023-2024 (monovalent XBB.1.5) COVID-19 vaccination for all persons aged ≥6 months to prevent COVID-19, including severe disease. However, few estimates of updated vaccine effectiveness (VE) against medically attended illness are available. This analysis evaluated VE of an updated COVID-19 vaccine dose against COVID-19-associated emergency department (ED) or urgent care (UC) encounters and hospitalization among immunocompetent adults aged ≥18 years during September 2023-January 2024 using a test-negative, case-control design with data from two CDC VE networks. VE against COVID-19-associated ED/UC encounters was 51% (95% CI = 47%-54%) during the first 7-59 days after an updated dose and 39% (95% CI = 33%-45%) during the 60-119 days after an updated dose. VE estimates against COVID-19-associated hospitalization from two CDC VE networks were 52% (95% CI = 47%-57%) and 43% (95% CI = 27%-56%), with a median interval from updated dose of 42 and 47 days, respectively. Updated COVID-19 vaccine provided increased protection against COVID-19-associated ED/UC encounters and hospitalization among immunocompetent adults. These results support CDC recommendations for updated 2023-2024 COVID-19 vaccination. All persons aged ≥6 months should receive updated 2023-2024 COVID-19 vaccine.
Download full-text PDF |
Source |
|---|---|
| http://www.ncbi.nlm.nih.gov/pmc/articles/PMC10907041 | PMC |
| http://dx.doi.org/10.15585/mmwr.mm7308a5 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Impact of health promotion strategies on HPV vaccination uptake: A descriptive epidemiological study (2019-2024).
PLoS One
September 2025
Institute of Public Health of Vojvodina, Novi Sad, Serbia.
Introduction/objectives: The effectiveness of vaccines depends not only on resource availability but also on broad public acceptance and the uptake of widely accessible vaccines. A vaccination campaign is a strategically coordinated initiative designed to enhance vaccine coverage within a specific population. This study evaluated the impact of health promotion strategies (HPS), including social marketing and education, on human papillomavirus (HPV) vaccine uptake among adolescents aged 9-19 years in City of Novi Sad, Serbia (population ~300,000).
View Article and Find Full Text PDFThe XBB.1.5 COVID-19 vaccine elicits a durable antibody response to ancestral and XBB.1.5 SARS-CoV-2 spike proteins.
Sci Transl Med
September 2025
Center for Childhood Infections and Vaccines, Children's Healthcare of Atlanta, Division of Infectious Diseases, Department of Pediatrics, Emory University School of Medicine, Atlanta, GA 30322, USA.
The rapid emergence of divergent SARS-CoV-2 variants led to a 2023-2024 update of the COVID-19 mRNA vaccine to a monovalent version containing the XBB.1.5 SARS-CoV-2 spike antigen.
View Article and Find Full Text PDFA geographical database of Iberian peatland and swob records.
Data Brief
October 2025
Centre of Geographical Studies, Institute of Geography and Spatial Planning, University of Lisbon, Rua Branca Edmée Marques, 1600-276 Lisboa, Portugal.
Recent efforts have compiled distribution data on peatlands in the Iberian Peninsula. However, the criteria used to define these ecosystems have often been derived from regions where climates are wetter and peatlands are more widespread. As a result, in this region, many peat-accumulating wetlands were overlooked.
View Article and Find Full Text PDFParental intent to vaccinate children with the updated 2023-2024 COVID-19 vaccine.
Vaccine
August 2025
Kaiser Permanente Center for Health Research, Portland, OR, USA.
Background: The updated 2023-24 COVID-19 vaccine was available in the United States beginning September 2023. Our objective was to identify reasons for decisions related to vaccination of children in the household.
Methods: In December 2023, adults in Oregon and Washington were asked whether they or their household children had received the 2023-24 COVID-19 vaccination.
Cost-Effectiveness of 2023-2024 COVID-19 Vaccination in US Adults.
JAMA Netw Open
August 2025
Centers for Disease Control and Prevention, Atlanta, Georgia.
Importance: Evidence is needed on the economic favorability of a 2023-2024 COVID-19 vaccination program to support policy decisions on recommendations for COVID-19 vaccination.
Objective: To measure the cost-effectiveness of vaccination with a 2023-2024 COVID-19 mRNA vaccine in adults aged 18 years or older compared with no updated vaccination (with a 2023-2024 vaccine).
Design, Setting, And Participants: This decision analytic modeling study used a simulation model to compare outcomes for hypothetical cohorts of vaccinated and unvaccinated, immunocompetent adults stratified by age (18-49 years, 50-64 years, and ≥65 years).